• Mutation; HGNC; HGNC:11998; TP53; Simple; c.673-2A>T (IVS6-2A>T); ClinVar=VCV000635388; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=16203773; PubMed=29970484; PubMed=33802339).
  

PubMed=8725545; DOI=10.3109/00016489609137854
Pekkola-Heino K., Servomaa K., Kiuru A., Grenman R.
Increased radiosensitivity is associated with p53 mutations in cell lines derived from oral cavity carcinoma.
Acta Oto-Laryngol. 116:341-344(1996)

PubMed=16203773; DOI=10.1158/1078-0432.CCR-05-0378
Mandic R., Schamberger C.J., Muller J.F., Geyer M., Zhu L., Carey T.E., Grenman R., Dunne A.A., Werner J.A.
Reduced cisplatin sensitivity of head and neck squamous cell carcinoma cell lines correlates with mutations affecting the COOH-terminal nuclear localization signal of p53.
Clin. Cancer Res. 11:6845-6852(2005)

PubMed=16331601; DOI=10.1002/ijc.21514
Muller A., Sonkoly E., Eulert C., Gerber P.A., Kubitza R., Schirlau K., Franken-Kunkel P., Poremba C., Snyderman C.H., Klotz L.-O., Ruzicka T., Bier H., Zlotnik A., Whiteside T.L., Homey B., Hoffmann T.K.
Chemokine receptors in head and neck cancer: association with metastatic spread and regulation during chemotherapy.
Int. J. Cancer 118:2147-2157(2006)

PubMed=17312569; DOI=10.1002/hed.20478
Lin C.J., Grandis J.R., Carey T.E., Gollin S.M., Whiteside T.L., Koch W.M., Ferris R.L., Lai S.Y.
Head and neck squamous cell carcinoma cell lines: established models and rationale for selection.
Head Neck 29:163-188(2007)

PubMed=18487078; DOI=10.1016/j.oraloncology.2008.02.006
Hoffmann T.K., Sonkoly E., Hauser U., van Lierop A., Whiteside T.L., Klussmann J.P., Hafner D., Schuler P.J., Friebe-Hoffmann U., Scheckenbach K., Erjala K., Grenman R., Schipper J., Bier H., Balz V.
Alterations in the p53 pathway and their association with radio- and chemosensitivity in head and neck squamous cell carcinoma.
Oral Oncol. 44:1100-1109(2008)

PubMed=29970484; DOI=10.1158/1535-7163.MCT-17-0733
Lepikhova T., Karhemo P.-R., Louhimo R., Yadav B., Murumagi A., Kulesskiy E., Kivento M., Sihto H., Grenman R., Syrjanen S.M., Kallioniemi O.-P., Aittokallio T., Wennerberg K., Joensuu H., Monni O.
Drug-sensitivity screening and genomic characterization of 45 HPV-negative head and neck carcinoma cell lines for novel biomarkers of drug efficacy.
Mol. Cancer Ther. 17:2060-2071(2018)

PubMed=30135316; DOI=10.1172/jci.insight.122204; PMCID=PMC6141174
Jamieson S.M.F., Tsai P., Kondratyev M.K., Budhani P., Liu A., Senzer N.N., Chiorean E.G., Jalal S.I., Nemunaitis J.J., Kee D., Shome A., Wong W.W., Li D., Poonawala-Lohani N., Kakadia P.M., Knowlton N.S., Lynch C.R.H., Hong C.R., Lee T.W., Grenman R., Caporiccio L., McKee T.D., Zaidi M., Butt S., Macann A.M.J., McIvor N.P., Chaplin J.M., Hicks K.O., Bohlander S.K., Wouters B.G., Hart C.P., Print C.G., Wilson W.R., Curran M.A., Hunter F.W.
Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma.
JCI Insight 3:e122204.1-e122204.19(2018)

DOI=10.1158/1538-7445.AM2020-507
Kondratyev M.K., Pesic A., Dvorkin-Sheva A., Ketela T., Moffat J., Koritzinsky M., Wouters B.G.
Repurposing of FDA approved drugs for treatment of metastatic HNSCC.
Cancer Res. 80 Suppl. 16:507-507(2020)

PubMed=33802339; DOI=10.3390/cancers13051069; PMCID=PMC7959143
Gottgens E.-L., Ansems M., Leenders W.P.J., Bussink J., Span P.N.
Genotyping and characterization of HPV status, hypoxia, and radiosensitivity in 22 head and neck cancer cell lines.
Cancers (Basel) 13:1069.1-1069.12(2021)